NCT06260410招募中不适用
Data Collection in Lutetium Treated Prostate Cancer: Recording of Progression and Tumor Characteristics
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 150
- 试验地点
- 1
- 主要终点
- Overall survival
研究概览
简要总结
This prospective study aims to collect data and blood biomarkers from patients undergoing Lu-PSMA therapy at the Erasmus MC. In doing so, it will provide real-world efficacy and safety data on the drug, gather dosimetry data and explore putative biomarkers to identify patients who most benefit from Lu-PSMA treatment.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Participants should be at least 18 years old.
- •Participants should be able to understand the written information and be able to provide informed consent.
- •Participants are planned to start treatment with Lu-PSMA as a part of regular clinical care.
排除标准
- •None applicable
结局指标
主要结局
Overall survival
时间窗: 44 months
Overall survival will be defined as the time from inclusion to death from any cause.
次要结局
- Progression free survival(44 months)
- Heterogeneity of PSMA-positivity(44 months)
- Effect of CTC PSMA expression on response to treatment.(44 months)
- PSMA-PET scan data and response to treatment.(44 months)
- Effect of biomarkers in blood on response to treatment.(44 months)
研究者
S. L. W. (Stijn) Koolen
Assistant Professor, Hospital Pharmacist, Clinical Pharmacologist
Erasmus Medical Center
研究点 (1)
Loading locations...
相似试验
尚未招募
不适用
Data collection in Lutetium Treated Prostate cancer: Recording of Progression and Tumor Characteristicsmetastatic castration-resistant prostate cancer10038597Prostate cancerNL-OMON56531Erasmus MC, Universitair Medisch Centrum Rotterdam150
已完成
不适用
Validation of the Stockholm3 Test for Detection of Prostate Cancer in the Swiss PopulationLocalized CarcinomaProstate CancerNCT05294627University Hospital, Basel, Switzerland380
已完成
不适用
Observational Study of Docetaxel Exposure in Metastatic Prostate Cancer PatientsProstate CancerNCT02376296Saladax Biomedical, Inc.35
已完成
不适用
Biomarkers in Patients Undergoing Transrectal Ultrasound Prostate BiopsyProstate CancerNCT00373035Wake Forest University Health Sciences60
撤回
不适用
Determination of Assay Cut-Off for the RadTox Test in Prostate Cancer Patients to Predict GI Radiation ToxicityProstate CancerNCT04580667DiaCarta, Inc.250